Table 3.
Author | Study design | Patients, n | Treatment | Incidence of HC,% (P-value) | Adverse effects, % (P-value) |
---|---|---|---|---|---|
Bladder irrigation | |||||
Hadjibabaie et al. (2008) [44] | Non-randomised, controlled | HSCT patients, 40 | Bladder irrigation vs no bladder irrigation | 32 vs 50 (NS) | UTI: 32.5 vs 20.0 (NS) |
Turkeri et al. (1995) [45] | Retrospective | HSCT patients, 199 | Bladder irrigation vs no bladder irrigation | 23 vs 53 (<0.004) | UTI: 16.0 vs 14.0 (NS) |
Moderate to severe discomfort and bladder spasms: 6.0 (NS) | |||||
Atkinson et al. (1991) [48] | Prospective, randomised | BMT patients, 22 | Bladder irrigation vs no bladder irrigation | 48 vs 29* | Not reported |
52 vs 38† (NS, irrigation vs no irrigation) | |||||
Hyperhydration and forced diuresis | |||||
Trotman et al. (1999) [49] | Prospective | HSCT or BMT patients, 681 | Hyperhydration and forced diuresis | HC: 18.2 | Not reported |
Grade 3 or 4: 3.4 | |||||
Mesna | |||||
Murphy et al. (1994) [50] | Retrospective | BMT patients, 227 | Hyperhydration + mesna vs hyperhydration alone | 16 vs 8 (0.08) | One patient receiving hyperhydration alone developed a bladder perforation, requiring surgical repair |
Vose et al. (1993) [52] | Prospective, randomised | BMT patients, 200 | Mesna vs bladder irrigation | 18 vs 18 (NS)‡ | UTI: 14 vs 27 (0.03) |
Shepherd et al. (1991) [51] | Randomised | BMT patients, 100 | Mesna vs hyperhydration | 33 vs 20 (NS) | No unexpected toxicities |
NS, not statistically significant.
Patients receiving busulfan + cyclophosphamide + RT or cyclophosphamide + RT;
Patients receiving busulfan + cyclophosphamide;
Grade III/IV haematuria.